Sandbox Captopril tablet: Difference between revisions
No edit summary |
No edit summary |
||
| Line 11: | Line 11: | ||
Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. | Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. | ||
|fdaLIADAdult====== | |fdaLIADAdult======Hypertension===== | ||
* Dosing Information | * Dosing Information | ||
:* ( | :* Initial dose: '''Captopril 25 mg PO bid''' or '''Captopril 25 mg PO tid'''; may be increased after 1 to 2 weeks to '''Captopril 50 mg PO bid''' or '''Captopril 50 mg PO tid''', then to ''' Captopril 100 to 150 mg PO bid/tid''' (in combination with a thiazide diuretic) if needed (MAX 450 mg daily) | ||
===== | Captopril tablets, USP are indicated for the treatment of [[hypertension]]. | ||
In using captopril, consideration should be given to the risk of [[neutropenia]]/[[agranulocytosis]]. | |||
Captopril may be used as initial therapy for patients with normal renal function, in whom the risk is relatively low. In patients with [[impaired renal function]], particularly those with [[collagen vascular disease]], captopril should be reserved for [[hypertensive]]s who have either developed unacceptable side effects on other drugs, or have failed to respond satisfactorily to drug combinations. | |||
Captopril is effective alone and in combination with other antihypertensive agents, especially [[thiazide]]-type [[diuretics]]. The [[blood pressure]] lowering effects of captopril and [[thiazides]] are approximately additive. | |||
=====Heart Failure===== | |||
* Dosing Information | |||
:* Initial dose: (patients with normal or low blood pressure, vigorous diuretic therapy, volume depletion) '''Captopril 6.25 to 12.5 mg PO tid''' | |||
:* Initial dose: '''Captopril PO 25 mg tid''' | |||
:* Maintenance dose: '''Captopril 50 to 100 mg PO tid''' (MAX 450 mg PO daily) | |||
Captopril tablets, USP are indicated in the treatment of [[congestive heart failure]] usually in combination with [[diuretics]] and [[digitalis]]. The beneficial effect of captopril in [[heart failure]] does not require the presence of [[digitalis]], however, most controlled clinical trial experience with captopril has been in patients receiving [[digitalis]], as well as [[diuretic]] treatment. | |||
=====Left Ventricular Dysfunction After Myocardial Infarction===== | |||
* Dosing Information | |||
:* Initial dose: '''Captopril 6.25 mg PO''' for one dose starting as early as 3 days after myocardial infarction, | |||
:* Maintenance dose: '''Captopril 12.5 mg tid''' a day increased to '''25 mg PO tid''' a day in several days; target dose '''50 mg PO tid''' over the next several weeks as tolerated | |||
Captopril tablets, USP are indicated to improve survival following [[myocardial infarction]] in clinically stable patients with [[left ventricular dysfunction]] manifested as an [[ejection fraction]] ≤40% and to reduce the incidence of overt [[heart failure]] and subsequent hospitalizations for [[congestive heart failure]] in these patients. | |||
=====Diabetic Nephropathy===== | |||
* Dosing Information | * Dosing Information | ||
:* ( | :* (type 1 diabetes mellitus) '''Captopril 25 mg PO tid''' | ||
:* (type 2 diabetes mellitus) '''Captopril 12.5 mg bid''', increased to '''Captopril 12.5 mg tid''' after 3 months | |||
Captopril tablets, USP are indicated for the treatment of [[diabetic nephropathy]] ([[proteinuria]] >500 mg/day) in patients with [[type I insulin-dependent diabetes mellitus]] and [[retinopathy]]. Captopril decreases the rate of progression of [[renal insufficiency]] and development of serious adverse clinical outcomes (death or need for renal transplantation or dialysis). | |||
In considering use of captopril, it should be noted that in controlled trials [[ACE inhibitors]] have an effect on blood pressure that is less in black patients than in non-blacks. In addition, ACE inhibitors (for which adequate data are available) cause a higher rate of [[angioedema]] in black than in non-black patients. | |||
|offLabelAdultGuideSupport======Condition 1===== | |offLabelAdultGuideSupport======Condition 1===== | ||
Revision as of 20:04, 1 May 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2], Amr Marawan, M.D. [3]
Disclaimer
WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.
Black Box Warning
|
Fetal Toxicity
See full prescribing information for complete Boxed Warning.
When pregnancy is detected, discontinue captopril as soon as possible.
Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus.
|
Overview
Sandbox Captopril tablet is an Angiontensin converting enzyme inhibitor that is FDA approved for the {{{indicationType}}} of hypertension, heart failure, left ventricular dysfunction after myocardial infarction, diabetic nephropathy. There is a Black Box Warning for this drug as shown here. Common adverse reactions include hypotension, rash, hyperkalemia, disorder of taste, cough.
Adult Indications and Dosage
FDA-Labeled Indications and Dosage (Adult)
Hypertension
- Dosing Information
- Initial dose: Captopril 25 mg PO bid or Captopril 25 mg PO tid; may be increased after 1 to 2 weeks to Captopril 50 mg PO bid or Captopril 50 mg PO tid, then to Captopril 100 to 150 mg PO bid/tid (in combination with a thiazide diuretic) if needed (MAX 450 mg daily)
Captopril tablets, USP are indicated for the treatment of hypertension.
In using captopril, consideration should be given to the risk of neutropenia/agranulocytosis.
Captopril may be used as initial therapy for patients with normal renal function, in whom the risk is relatively low. In patients with impaired renal function, particularly those with collagen vascular disease, captopril should be reserved for hypertensives who have either developed unacceptable side effects on other drugs, or have failed to respond satisfactorily to drug combinations.
Captopril is effective alone and in combination with other antihypertensive agents, especially thiazide-type diuretics. The blood pressure lowering effects of captopril and thiazides are approximately additive.
Heart Failure
- Dosing Information
- Initial dose: (patients with normal or low blood pressure, vigorous diuretic therapy, volume depletion) Captopril 6.25 to 12.5 mg PO tid
- Initial dose: Captopril PO 25 mg tid
- Maintenance dose: Captopril 50 to 100 mg PO tid (MAX 450 mg PO daily)
Captopril tablets, USP are indicated in the treatment of congestive heart failure usually in combination with diuretics and digitalis. The beneficial effect of captopril in heart failure does not require the presence of digitalis, however, most controlled clinical trial experience with captopril has been in patients receiving digitalis, as well as diuretic treatment.
Left Ventricular Dysfunction After Myocardial Infarction
- Dosing Information
- Initial dose: Captopril 6.25 mg PO for one dose starting as early as 3 days after myocardial infarction,
- Maintenance dose: Captopril 12.5 mg tid a day increased to 25 mg PO tid a day in several days; target dose 50 mg PO tid over the next several weeks as tolerated
Captopril tablets, USP are indicated to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction manifested as an ejection fraction ≤40% and to reduce the incidence of overt heart failure and subsequent hospitalizations for congestive heart failure in these patients.
Diabetic Nephropathy
- Dosing Information
- (type 1 diabetes mellitus) Captopril 25 mg PO tid
- (type 2 diabetes mellitus) Captopril 12.5 mg bid, increased to Captopril 12.5 mg tid after 3 months
Captopril tablets, USP are indicated for the treatment of diabetic nephropathy (proteinuria >500 mg/day) in patients with type I insulin-dependent diabetes mellitus and retinopathy. Captopril decreases the rate of progression of renal insufficiency and development of serious adverse clinical outcomes (death or need for renal transplantation or dialysis).
In considering use of captopril, it should be noted that in controlled trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, ACE inhibitors (for which adequate data are available) cause a higher rate of angioedema in black than in non-black patients.
Off-Label Use and Dosage (Adult)
Guideline-Supported Use
Condition 1
- Developed by: (Organisation)
- Class of Recommendation: (Class) (Link)
- Strength of Evidence: (Category A/B/C) (Link)
- Dosing Information/Recommendation
- (Dosage)
Condition 2
- Developed by: (Organisation)
- Class of Recommendation: (Class) (Link)
- Strength of Evidence: (Category A/B/C) (Link)
- Dosing Information/Recommendation
- (Dosage)
Non–Guideline-Supported Use
Condition 1
- Dosing Information
- (Dosage)
Condition 2
- Dosing Information
- (Dosage)
Condition 3
- Dosing Information
- (Dosage)
Pediatric Indications and Dosage
FDA-Labeled Indications and Dosage (Pediatric)
Condition 1
- Dosing Information
- (Dosage)
Condition 2
- Dosing Information
- (Dosage)
Off-Label Use and Dosage (Pediatric)
Guideline-Supported Use
Condition 1
- Developed by: (Organisation)
- Class of Recommendation: (Class) (Link)
- Strength of Evidence: (Category A/B/C) (Link)
- Dosing Information/Recommendation
- (Dosage)
Condition 2
- Developed by: (Organisation)
- Class of Recommendation: (Class) (Link)
- Strength of Evidence: (Category A/B/C) (Link)
- Dosing Information/Recommendation
- (Dosage)
Non–Guideline-Supported Use
Condition 1
- Dosing Information
- (Dosage)
Condition 2
- Dosing Information
- (Dosage)
Condition 3
- Dosing Information
- (Dosage)
Contraindications
- Condition 1
- Condition 2
- Condition 3
- Condition 4
- Condition 5
Warnings
|
Fetal Toxicity
See full prescribing information for complete Boxed Warning.
When pregnancy is detected, discontinue captopril as soon as possible.
Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus.
|
Conidition 1
(Description)
Conidition 2
(Description)
Conidition 3
(Description)
Adverse Reactions
Clinical Trials Experience
Central Nervous System
- (list/description of adverse reactions)
Cardiovascular
- (list/description of adverse reactions)
Respiratory
- (list/description of adverse reactions)
Gastrointestinal
- (list/description of adverse reactions)
Hypersensitive Reactions
- (list/description of adverse reactions)
Miscellaneous
- (list/description of adverse reactions)
Condition 2
Central Nervous System
- (list/description of adverse reactions)
Cardiovascular
- (list/description of adverse reactions)
Respiratory
- (list/description of adverse reactions)
Gastrointestinal
- (list/description of adverse reactions)
Hypersensitive Reactions
- (list/description of adverse reactions)
Miscellaneous
- (list/description of adverse reactions)
Postmarketing Experience
(Description)
Drug Interactions
- Drug 1
- Drug 2
- Drug 3
- Drug 4
- Drug 5
Drug 1
(Description)
Drug 2
(Description)
Drug 3
(Description)
Drug 4
(Description)
Drug 5
(Description)
Use in Specific Populations
Pregnancy
Pregnancy Category (FDA):
(Description)
Pregnancy Category (AUS):
(Description)
Labor and Delivery
(Description)
Nursing Mothers
(Description)
Pediatric Use
(Description)
Geriatic Use
(Description)
Gender
(Description)
Race
(Description)
Renal Impairment
(Description)
Hepatic Impairment
(Description)
Females of Reproductive Potential and Males
(Description)
Immunocompromised Patients
(Description)
Others
(Description)
Administration and Monitoring
Administration
(Oral/Intravenous/etc)
Monitoring
Condition 1
(Description regarding monitoring, from Warnings section)
Condition 2
(Description regarding monitoring, from Warnings section)
Condition 3
(Description regarding monitoring, from Warnings section)
IV Compatibility
Solution
Compatible
- Solution 1
- Solution 2
- Solution 3
Not Tested
- Solution 1
- Solution 2
- Solution 3
Variable
- Solution 1
- Solution 2
- Solution 3
Incompatible
- Solution 1
- Solution 2
- Solution 3
Y-Site
Compatible
- Solution 1
- Solution 2
- Solution 3
Not Tested
- Solution 1
- Solution 2
- Solution 3
Variable
- Solution 1
- Solution 2
- Solution 3
Incompatible
- Solution 1
- Solution 2
- Solution 3
Admixture
Compatible
- Solution 1
- Solution 2
- Solution 3
Not Tested
- Solution 1
- Solution 2
- Solution 3
Variable
- Solution 1
- Solution 2
- Solution 3
Incompatible
- Solution 1
- Solution 2
- Solution 3
Syringe
Compatible
- Solution 1
- Solution 2
- Solution 3
Not Tested
- Solution 1
- Solution 2
- Solution 3
Variable
- Solution 1
- Solution 2
- Solution 3
Incompatible
- Solution 1
- Solution 2
- Solution 3
TPN/TNA
Compatible
- Solution 1
- Solution 2
- Solution 3
Not Tested
- Solution 1
- Solution 2
- Solution 3
Variable
- Solution 1
- Solution 2
- Solution 3
Incompatible
- Solution 1
- Solution 2
- Solution 3
Overdosage
Acute Overdose
Signs and Symptoms
(Description)
Management
(Description)
Chronic Overdose
Signs and Symptoms
(Description)
Management
(Description)
Pharmacology
Sandbox Captopril tablet
| |
| Systematic (IUPAC) name | |
| ? | |
| Identifiers | |
| CAS number | ? |
| ATC code | ? |
| PubChem | ? |
| Chemical data | |
| Formula | ? |
| Mol. mass | ? |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Mechanism of Action
(Description)
Structure
(Description with picture)
Pharmacodynamics
(Description)
Pharmacokinetics
(Description)
Nonclinical Toxicology
(Description)
Clinical Studies
Condition 1
(Description)
Condition 2
(Description)
Condition 3
(Description)
How Supplied
(Description)
Storage
There is limited information regarding Sandbox Captopril tablet Storage in the drug label.
Images
Drug Images
{{#ask: Page Name::Sandbox Captopril tablet |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}
Package and Label Display Panel
{{#ask: Label Page::Sandbox Captopril tablet |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}
Patient Counseling Information
(Patient Counseling Information)
Precautions with Alcohol
Alcohol-Sandbox Captopril tablet interaction has not been established. Talk to your doctor regarding the effects of taking alcohol with this medication.
Brand Names
There is limited information regarding Sandbox Captopril tablet Brand Names in the drug label.
Look-Alike Drug Names
- (Paired Confused Name 1a) — (Paired Confused Name 1b)
- (Paired Confused Name 2a) — (Paired Confused Name 2b)
- (Paired Confused Name 3a) — (Paired Confused Name 3b)
Drug Shortage Status
Drug Shortage
Price
References
The contents of this FDA label are provided by the National Library of Medicine.